Clinical Trial

A Phase 2 Study of ABSK043 Combined With Osimertinib

Name: A Phase 2 Study of ABSK043 Combined With Osimertinib — clinical trial record (NCT07710612)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a phase 2, open-Label study to evaluate the efficacy and safety of ABSK043 Combined with Osimertinib in participants with EGFR-Mutated locally advanced or metastatic Non-Small Cell Lung Cancer

Trial Details

NCT Number	NCT07710612
Lead Sponsor	Abbisko Therapeutics Co, Ltd Collaborators: AstraZeneca
Conditions	Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive
Enrollment	72 participants
Start Date	2026-08-31
Primary Completion	2029-12-31 (estimated)
Study Completion	2030-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-17